Modified FOLFIRINOX compared to Gemcitabine & nab-Paclitaxel in advanced pancreatic ductal adenocarcinoma - results of a match-pair analysis

Modified FOLFIRINOX compared to Gemcitabine & nab-Paclitaxel in advanced pancreatic ductal adenocarcinoma - results of a match-pair analysis

Background & objectives: FOLFIRINOX and gemcitabine plus nab-paclitaxel (GN) are the most commonly used regimens in advanced pancreatic ductal adenocarcinomas (PDACs). As there is limited data on comparison of these two regimens, the present study was aimed to compare survivals and tolerance for...

Full description

Bibliographic Details
Main Authors: Anant Ramaswamy, Darshit Shah, Prabhat Bhargava, Sujay Srinivas, Sadhana Kannan, Minit Shah, Mannavi Suman, Shasanka Das, Mehak Trikha, Vikas Ostwal
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2023-01-01
Series:Indian Journal of Medical Research
Subjects:
advanced pancreatic cancer - gemcitabine-nab-paclitaxel - match-pair
modified folfirinox - survival - toxicity
Online Access:http://www.ijmr.org.in/article.asp?issn=0971-5916;year=2023;volume=157;issue=1;spage=57;epage=65;aulast=Ramaswamy

Internet

http://www.ijmr.org.in/article.asp?issn=0971-5916;year=2023;volume=157;issue=1;spage=57;epage=65;aulast=Ramaswamy

Similar Items